Biogen Idec, Inc. (Massachusetts) Release: PLEGRIDY™ (Peginterferon Beta-1a) Two-Year Data Confirm Maintenance Of Efficacy And Safety In Multiple Sclerosis Patients

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Today Biogen Idec (NASDAQ: BIIB) announced new data from the second year of its Phase 3 ADVANCE clinical trial that show the positive treatment effects of PLEGRIDY™ (peginterferon beta-1a) were maintained in people with relapsing forms of multiple sclerosis (RMS) beyond the first year of the study. These results were presented at the sixth Triennial Joint Meeting of the Americas Committee for Treatment and Research in Multiple Sclerosis and the European Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS-ECTRIMS) in Boston.

Help employers find you! Check out all the jobs and post your resume.